Meeting
2022 ASCO Annual Meeting
TTI-621-03: A phase I/II study of TTI-621 in combination with doxorubicin in patients with unresectable or metastatic high-grade leiomyosarcoma (LMS).
Authors
Sant P. Chawla
Sarcoma Oncology Research Center, Santa Monica, CA
Sant P. Chawla , Ciara Marie Kelly , Erlinda Maria Gordon , Doris V. Quon , Ania Moradkhani , Victoria S. Chua-Alcala , Theresa M. Thompson , Anita Scheuber , Ingmar Bruns , Victoria E. Allgood , Sujana Movva
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Sarcoma
Track
Sarcoma
Sub Track
Soft Tissue Tumors
Clinical Trial Registration Number
NCT04996004
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr TPS11593)
DOI
10.1200/JCO.2022.40.16_suppl.TPS11593
Abstract #
TPS11593
Poster Bd #
491b
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
A phase 1b lead-in to a randomized phase 2 trial of lurbinectedin plus doxorubicin in leiomyosarcoma (LMS).
First Author: Gregory Michael Cote
Poster
2023 ASCO Annual Meeting
A phase I study of nanoparticle albumin-bound sirolimus (NAB-S) combined with pazopanib (PAZO) in patients with advanced soft tissue sarcoma (STS).
First Author: Lee D. Cranmer
Poster
2022 ASCO Annual Meeting
A phase II study of gemcitabine docetaxel combination in metastatic/unresectable locally advanced relapsed synovial sarcoma.
First Author: Ghazal Tansir
Poster
2020 ASCO Virtual Scientific Program
A pilot study evaluating the safety, tolerability, and efficacy of doxorubicin and pembrolizumab in patients with metastatic or unresectable soft tissue sarcoma.
First Author: Michael B. Livingston